Valuation: BOIRON

Market Cap 32Cr 36Cr 30Cr 27Cr 51Cr 3.45TCr 52Cr 359.79Cr 141.07Cr 1.8TCr 136.35Cr 133.44Cr 5.74TCr P/E 2024
41x
P/E 2025 16.1x
Enterprise Value 28Cr 31Cr 25Cr 23Cr 44Cr 2.94TCr 44Cr 306.47Cr 120.16Cr 1.53TCr 116.14Cr 113.67Cr 4.89TCr EV / Sales 2024
0.85x
EV / Sales 2025 0.95x
Free-Float
19.96%
Yield 2024
4.48%
Yield 2025 4.46%
1 day+3.91%
1 week+5.68%
Current month-7.00%
1 month-26.19%
3 months-30.60%
6 months-26.19%
Current year-38.61%
1 week 16.9
Extreme 16.9
19.5
1 month 16.9
Extreme 16.9
21.5
Current year 16.9
Extreme 16.9
30.95
1 year 16.9
Extreme 16.9
32.25
3 years 16.9
Extreme 16.9
43.96
5 years 16.9
Extreme 16.9
56.5
10 years 16.9
Extreme 16.9
92.7
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2025
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 65 01/07/2011
Director/Board Member 54 10/03/2010
Director/Board Member 51 23/05/2013
Date Insider Type Main position Quantity % Market Cap. Importance
29/10/23 Sell

Director

1,98,664 1.1323%
29/10/23 Sell

Director

4,62,964 2.6387%
29/10/23 Sell

Director

4,748 0.0271%
Change 5-day change 1-year change 3-year change Capi.($)
+3.91%+5.68%-32.36%-64.57% 36Cr
+0.43%+6.59%+56.57%+106.64% 1,12000Cr
+0.90%-2.25%+32.26%+63.73% 62TCr
+0.71%+3.24%+24.33%+91.33% 50TCr
-0.13%+5.98%+33.66%+50.18% 37TCr
+0.52%+0.24%+72.13%+40.11% 36TCr
-0.95%+4.70%+19.65%+42.71% 29TCr
-1.98%+3.73%-0.89%+10.43% 26TCr
-0.35%+4.25%+44.74%+52.06% 23TCr
-0.75%+3.32%+27.18%+94.07% 19TCr
Average +0.23%+3.82%+27.73%+48.67% 39.41TCr
Weighted average by Cap. +0.13%+3.83%+39.33%+71.81%

Financials

2024 2025
Net sales 49Cr 55Cr 45Cr 41Cr 78Cr 5.21TCr 79Cr 543.2Cr 212.98Cr 2.72TCr 205.85Cr 201.47Cr 8.66TCr 50Cr 56Cr 46Cr 42Cr 80Cr 5.35TCr 81Cr 558.29Cr 218.89Cr 2.79TCr 211.57Cr 207.07Cr 8.9TCr
Net income 1.13Cr 1.28Cr 1.05Cr 95.6L 1.8Cr 121.03Cr 1.83Cr 13Cr 4.95Cr 63Cr 4.79Cr 4.68Cr 201.35Cr 3.26Cr 3.67Cr 3.03Cr 2.75Cr 5.19Cr 348.53Cr 5.28Cr 36Cr 14Cr 181.88Cr 14Cr 13Cr 579.79Cr
Net Debt -4.97Cr -5.6Cr -4.61Cr -4.19Cr -7.91Cr -531.05Cr -8.04Cr -55Cr -22Cr -277.12Cr -21Cr -21Cr -883.43Cr -4.79Cr -5.38Cr -4.44Cr -4.04Cr -7.62Cr -510.94Cr -7.74Cr -53Cr -21Cr -266.63Cr -20Cr -20Cr -849.98Cr
Projected Income Statement - Annual - BOIRON
Logo BOIRON
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues. Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin. There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties). BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries. Net sales are distributed geographically as follows: France (43.5%), Europe (24%), North America (27.5%) and other (5%).
Employees
2,623
Date Price Change Volume
16/26/16 €18.60 +3.91% 9,099
15/26/15 €17.90 -0.56% 5,955
14/26/14 €18.00 +6.51% 4,223
13/26/13 €16.90 -2.03% 13,940
12/26/12 €17.25 -1.99% 7,127

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - BOIRON